Reports Q4 revenue $47.54M, consensus $45.29M. “2024 was a terrific year for Geron (GERN) and for RYTELO, our first-in-class telomerase inhibitor, which we believe represents a highly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback